Eli Lilly (LLY) said Friday that new results showed that 50% of patients with moderate-to-severe atopic dermatitis, or eczema, achieved completely clear skin at three years after receiving single monthly maintenance injection of Ebglyss.

The patients were among the Ebglyss week 16 responders from the monotherapy trials, the company said.

Eli Lilly also said 87% achieved or maintained "almost-clear" skin at three years with Ebglyss based on data from a long-term extension study.

Ebglyss was approved by the US Food and Drug Administration in 2024 as a first-line monotherapy biologic treatment option after topical prescription therapies.

The company also said that based on additional studies, Ebglyss improved symptoms such as itch, skin pain and sleep loss due to itch.